You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameEthyl biscoumacetate
Accession NumberDB08794
TypeSmall Molecule
GroupsWithdrawn
DescriptionEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Structure
Thumb
Synonyms
Ethyl bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)acetate
Ethyldicoumarol
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PelentanNot Available
TromexanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII08KL644731
CAS number548-00-5
WeightAverage: 408.362
Monoisotopic: 408.084517475
Chemical FormulaC22H16O8
InChI KeyJCLHQFUTFHUXNN-UHFFFAOYSA-N
InChI
InChI=1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
IUPAC Name
ethyl 2,2-bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
SMILES
CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AcetaminophenAcetaminophen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AcetohexamideAcetohexamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AllopurinolAllopurinol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AllylestrenolThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Allylestrenol.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AltrenogestThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AmdinocillinAmdinocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
AmineptineAmineptine may increase the anticoagulant activities of Ethyl biscoumacetate.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AmiodaroneAmiodarone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AmitriptylineAmitriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AmobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Amobarbital.Approved, Illicit
AmoxicillinAmoxicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
AmpicillinAmpicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AncrodAncrod may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Antithrombin III humanEthyl biscoumacetate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ApremilastApremilast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AprotininThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
AtorvastatinAtorvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
AzathioprineAzathioprine may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
AzelastineAzelastine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AzidocillinAzidocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
AzithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Azithromycin.Approved
AzlocillinAzlocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BacampicillinBacampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BarbexacloneThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.Illicit
BatroxobinBatroxobin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Benzathine benzylpenicillinBenzathine benzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
BenzylpenicillinBenzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
Benzylpenicillin PotassiumBenzylpenicillin Potassium may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Benzylpenicilloyl PolylysineBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BeraprostBeraprost may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
BezafibrateBezafibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BicalutamideThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Bicalutamide.Approved
BivalirudinBivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
BosentanThe metabolism of Ethyl biscoumacetate can be increased when combined with Bosentan.Approved, Investigational
BromfenacBromfenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
BucillamineBucillamine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CapecitabineThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Capecitabine.Approved, Investigational
CarbamazepineThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbenicillinCarbenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CarbimazoleCarbimazole may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
CarbomycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Carbomycin.Vet Approved
CarindacillinCarindacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CarprofenCarprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
CefacetrileCefacetrile may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefaclorCefaclor may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefadroxilCefadroxil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved, Withdrawn
CefalotinCefalotin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CefamandoleCefamandole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefapirinCefapirin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CefazolinCefazolin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefiximeCefixime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefmenoximeCefmenoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefmetazoleCefmetazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefminoxCefminox may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefonicidCefonicid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefoperazoneCefoperazone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CeforanideCeforanide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefotaximeCefotaxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefotetanCefotetan may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefotiamCefotiam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefoxitinCefoxitin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefpodoximeCefpodoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CefradineCefradine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefroxadineCefroxadine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CeftazidimeCeftazidime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CeftizoximeCeftizoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CeftriaxoneCeftriaxone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CefuroximeCefuroxime may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CelecoxibCelecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CephalexinCephalexin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CephaloglycinCephaloglycin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CephaloridineCephaloridine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
CerivastatinCerivastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
CertoparinEthyl biscoumacetate may increase the anticoagulant activities of Certoparin.Approved
Chloral hydrateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolChloramphenicol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ChloroquineChloroquine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ChlorpropamideChlorpropamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ChlortetracyclineChlortetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CilostazolCilostazol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CimetidineCimetidine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CinoxacinCinoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
CiprofibrateCiprofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CiprofloxacinCiprofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
CitalopramCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Citric AcidCitric Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Clarithromycin.Approved
ClofibrateClofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ClomipramineClomipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Nutraceutical
CloxacillinCloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
Coenzyme Q10Coenzyme Q10 may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
CranberryCranberry may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
CyclacillinCyclacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
CyclobenzaprineCyclobenzaprine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DalteparinDalteparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
DapoxetineDapoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
DemeclocyclineDemeclocycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DesipramineDesipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DesirudinEthyl biscoumacetate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DesogestrelDesogestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.Approved
DexmethylphenidateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dexmethylphenidate.Approved
DextranEthyl biscoumacetate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ethyl biscoumacetate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ethyl biscoumacetate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ethyl biscoumacetate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
DicloxacillinDicloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
DienogestDienogest may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DihydrotestosteroneDihydrotestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.Illicit
DipyridamoleDipyridamole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DisulfiramThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Disulfiram.Approved
DitazoleDitazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
DosulepinDosulepin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DoxepinDoxepin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DoxycyclineDoxycycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dronedarone.Approved
DrospirenoneDrospirenone may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DuloxetineDuloxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
DydrogesteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
EbselenEbselen may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
EconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Econazole.Approved
Edetic AcidEdetic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EfavirenzThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinEnoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EpinastineEpinastine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ErythromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EsmirtazapineEsmirtazapine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
EsomeprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
EstramustineEstramustine may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EstriolEstriol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EstroneEstrone may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Estrone sulfateEstrone sulfate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Etacrynic acidThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EthanolThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Ethanol.Approved
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EthotoinEthotoin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Ethynodiol diacetateEthynodiol diacetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EtofibrateEtofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EtonogestrelEtonogestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
EtoperidoneEtoperidone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EtoposideEtoposide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ExenatideExenatide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FenofibrateFenofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FleroxacinFleroxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
FlucloxacillinFlucloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
FluconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluconazole.Approved
FluindioneEthyl biscoumacetate may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FlunixinFlunixin may increase the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
FluorouracilThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FluvastatinFluvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
FluvoxamineFluvoxamine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FondaparinuxEthyl biscoumacetate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
FosphenytoinFosphenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Fusidic AcidThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fusidic Acid.Approved
GabexateEthyl biscoumacetate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinGarenoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
GatifloxacinGatifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GefitinibGefitinib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GemfibrozilGemfibrozil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GemifloxacinGemifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
GenisteinGenistein may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
GestodeneGestodene may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
GestrinoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Gestrinone.Approved
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Ethyl biscoumacetate.Approved, Nutraceutical
GlibornurideGlibornuride may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
GliclazideGliclazide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlimepirideGlimepiride may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlipizideGlipizide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GliquidoneGliquidone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlisoxepideGlisoxepide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Glucagon recombinantGlucagon recombinant may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GlutethimideThe metabolism of Ethyl biscoumacetate can be increased when combined with Glutethimide.Approved, Illicit
GlyburideGlyburide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
GrepafloxacinGrepafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
GriseofulvinThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
HeminHemin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
HeparinHeparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
HexobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Hexobarbital.Approved
HigenamineHigenamine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
HirulogHirulog may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ethyl biscoumacetate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Nutraceutical
idraparinuxEthyl biscoumacetate may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
IfosfamideIfosfamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
IloprostIloprost may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
ImipramineImipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
IndalpineIndalpine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
IndobufenIndobufen may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ItraconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Itraconazole.Approved, Investigational
IvermectinIvermectin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
JosamycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Josamycin.Approved
Kct 0809Kct 0809 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
KetoconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
KitasamycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Kitasamycin.Experimental
L-CarnitineL-Carnitine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LansoprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Lansoprazole.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LevofloxacinLevofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethyl biscoumacetate.Approved
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LevothyroxineLevothyroxine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ethyl biscoumacetate.Approved
LiothyronineLiothyronine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
LiotrixLiotrix may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LisofyllineLisofylline may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
LixisenatideLixisenatide can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LomefloxacinLomefloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LovastatinLovastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
LynestrenolLynestrenol may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateMedroxyprogesterone acetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Megestrol acetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
MercaptopurineMercaptopurine may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
MesalazineMesalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MestranolMestranol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Ethyl biscoumacetate.Experimental
MethimazoleMethimazole may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
MethohexitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Methohexital.Approved
MethylphenidateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Methylphenobarbital.Approved
MethyltestosteroneMethyltestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MeticillinMeticillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MetronidazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Metronidazole.Approved
MevastatinMevastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental
MezlocillinMezlocillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MiconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ethyl biscoumacetate.Approved
MilrinoneMilrinone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MinocyclineMinocycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
MirtazapineMirtazapine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
MizoribineMizoribine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
MoxifloxacinMoxifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NadroparinEthyl biscoumacetate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
NafcillinNafcillin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
NaftifineNaftifine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Nalidixic AcidNalidixic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NaproxenNaproxen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
NCX 4016NCX 4016 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
NefazodoneNefazodone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
NemonoxacinNemonoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
NeomycinNeomycin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NimesulideNimesulide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
NomegestrolThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Nomegestrol.Approved
NorelgestrominNorelgestromin may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
NorethisteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
NorgestimateNorgestimate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
NorgestrelNorgestrel may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
NortriptylineNortriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Obinutuzumab.Approved
OfloxacinOfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OleandomycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OmeprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolOpipramol may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
OritavancinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Oritavancin.Approved, Investigational
OtamixabanOtamixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
OxacillinOxacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OxandroloneOxandrolone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
OxymetholoneOxymetholone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Illicit
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
OxytetracyclineOxytetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ParecoxibParecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ParoxetineParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PazufloxacinPazufloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
PefloxacinPefloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PentobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PhenobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Phenobarbital.Approved
PhenoxymethylpenicillinPhenoxymethylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
PhenytoinPhenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
PhylloquinonePhylloquinone may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PiperacillinPiperacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
PitavastatinPitavastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PivampicillinPivampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PivmecillinamPivmecillinam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PlasminPlasmin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
PosaconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PravastatinPravastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PrimidoneThe metabolism of Ethyl biscoumacetate can be increased when combined with Primidone.Approved, Vet Approved
Procaine benzylpenicillinProcaine benzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PropafenoneThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Propafenone.Approved
PropylthiouracilPropylthiouracil may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Protein CEthyl biscoumacetate may increase the anticoagulant activities of Protein C.Approved
Protein S humanEthyl biscoumacetate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEthyl biscoumacetate may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
PrulifloxacinPrulifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
PTC299PTC299 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
QuinidineQuinidine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
QuinineQuinine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ReviparinEthyl biscoumacetate may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
RifabutinThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifapentine.Approved
RivaroxabanEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
RosoxacinRosoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
RosuvastatinRosuvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
S EquolS Equol may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SCH-530348SCH-530348 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
SecobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Ethyl biscoumacetate.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
SertralineSertraline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
SimvastatinSimvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SolithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Solithromycin.Investigational
SparfloxacinSparfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SRT501SRT501 may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
St. John's WortThe metabolism of Ethyl biscoumacetate can be increased when combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
StreptokinaseStreptokinase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SucralfateSucralfate may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
SugammadexSugammadex may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulbactamSulbactam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulfadiazineSulfadiazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulfinpyrazoneThe metabolism of Ethyl biscoumacetate can be decreased when combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
SulodexideSulodexide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
SultamicillinSultamicillin may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
SuprofenSuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ethyl biscoumacetate.Approved
TamoxifenThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tamoxifen.Approved
TazobactamTazobactam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TegafurThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tegafur.Approved
TelithromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
TenecteplaseTenecteplase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
TestosteroneTestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TetracyclineTetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
ThiamylalThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiopental.Approved, Vet Approved
Thyroid, porcineThyroid, porcine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TianeptineTianeptine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TiboloneTibolone may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TicarcillinTicarcillin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Vet Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TinoridineTinoridine may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TipranavirTipranavir may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TolazamideTolazamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TolbutamideTolbutamide may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TolmetinTolmetin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ToremifeneToremifene may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Tositumomab.Approved
TramadolTramadol may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TrimipramineTrimipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
TroleandomycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinTrovafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Withdrawn
TylosinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tylosin.Vet Approved
UrokinaseUrokinase may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Investigational, Withdrawn
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ethyl biscoumacetate.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Ethyl biscoumacetate.Approved
VoriconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
Ym150Ethyl biscoumacetate may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Approved
ZeranolZeranol may decrease the anticoagulant activities of Ethyl biscoumacetate.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Ethyl biscoumacetate.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).

General ReferencesNot Available
External Links
ATC CodesB01AA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.937
Blood Brain Barrier+0.5382
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6415
P-glycoprotein inhibitor INon-inhibitor0.7527
P-glycoprotein inhibitor IINon-inhibitor0.7433
Renal organic cation transporterNon-inhibitor0.8741
CYP450 2C9 substrateNon-substrate0.7999
CYP450 2D6 substrateNon-substrate0.9049
CYP450 3A4 substrateNon-substrate0.6717
CYP450 1A2 substrateNon-inhibitor0.6524
CYP450 2C9 inhibitorInhibitor0.8453
CYP450 2D6 inhibitorNon-inhibitor0.9562
CYP450 2C19 inhibitorInhibitor0.6966
CYP450 3A4 inhibitorNon-inhibitor0.9273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6137
Ames testNon AMES toxic0.6498
CarcinogenicityNon-carcinogens0.9167
BiodegradationNot ready biodegradable0.7564
Rat acute toxicity2.7178 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.938
hERG inhibition (predictor II)Non-inhibitor0.896
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point153-154Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).
water solubility153 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0677 mg/mLALOGPS
logP2.18ALOGPS
logP1.67ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.82ChemAxon
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area119.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.95 m3·mol-1ChemAxon
Polarizability39.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCoumarins and derivatives
Sub ClassHydroxycoumarins
Direct Parent4-hydroxycoumarins
Alternative Parents
Substituents
  • 4-hydroxycoumarin
  • Benzopyran
  • 1-benzopyran
  • Pyranone
  • Pyran
  • Benzenoid
  • Heteroaromatic compound
  • Vinylogous acid
  • Carboxylic acid ester
  • Lactone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Oxacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organic oxygen compound
  • Carbonyl group
  • Organic oxide
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Manganese ion binding
Specific Function:
This enzyme has 2 functions: it catalyzes the production of glutamine and 4-aminobutanoate (gamma-aminobutyric acid, GABA), the latter in a pyridoxal phosphate-independent manner (By similarity). Essential for proliferation of fetal skin fibroblasts.
Gene Name:
GLUL
Uniprot ID:
P15104
Molecular Weight:
42064.15 Da
References
  1. Sharaev PN, Bogdanov NG, Sarycheva IK, Zhukova EE: [Allosteric regulation of glucosamine synthetase activity by naphthoquinone derivatives and ethyl ester of di-(4-oxycumarinyl-3)-acetic acid]. Biokhimiia. 1981 Feb;46(2):342-6. [PubMed:7195738 ]
Comments
comments powered by Disqus
Drug created on October 08, 2010 15:27 / Updated on August 17, 2016 12:24